Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models

• Main Authors: Zhiheng Yu (Author), Zihan Lei (Author), Xueting Yao (Author), Hengbang Wang (Author), Miao Zhang (Author), Zhe Hou (Author), Yafen Li (Author), Yangyu Zhao (Author), Haiyan Li (Author), Dongyang Liu (Author), Yifan Zhai (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Olverembatinib (HQP1351) is a third-generation BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) (including T315I-mutant disease), exhibits drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4, CYP2C9, CYP2C19, CYP1A2, and CYP2B6. A p...